VCs in £27m series-A for MiroBio

Advent Life Sciences and SR One also participated in the funding round. Members of all four investors will join the company's board of directors.

Advent Life Sciences is currently investing from its second-generation fund, which closed on $145.5m in 2014.

The fresh capital will be used to advance MiroBio's clinical programmes, expand its discovery efforts and expand its management team.

Company
MiroBio develops proprietary antibodies and variants to stimulate specific immune cell signals to harness the control mechanisms of the immune system for therapeutic benefit across a range of diseases. The company was established as a spin-out from the University of Oxford in 2019 and is based in Oxford with a team of eight.

People
Samsara Biocapital - Srini Akkaraju (managing general partner).
Advent Life Sciences - Shahzad Malik (director).
SROne – Eliot Charles (venture partner); Debbie Harland (director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• healthcare
• Advent Venture Partners
• United Kingdom